Introduction
============

Despite the known benefits of needle biopsy for diagnosing suspicious breast lesions, variability in the use of this technique has been documented in practice. As a metropolis with rapid social and economic development over the past 3 decades, Shanghai has a breast cancer incidence that surpasses all other cancer registries in the People's Republic of China.[@b1-ott-8-2865] Chinese patients have historically chosen open surgical biopsy (OSB) as the diagnostic method instead of needle biopsy due to the risk of triggering distant metastases. Over the last decade, however, breast cancer diagnosis in the People's Republic of China has greatly changed. Several disadvantages of traditional diagnostic procedures have been suggested, such as prolonged surgery time, drawbacks to neoadjuvant therapy, and surgery without a concrete pathological diagnosis. As a matter of course, it is important to make a rapid preoperative diagnosis to choose an appropriate treatment. Triple assessment, which consists of a physical examination, imaging modalities such as mammography and ultrasonography, and fine-needle aspiration, has been used to make a preoperative diagnosis.[@b2-ott-8-2865] However, the development of core needle biopsy (CNB) for use with breast lesions has led to a gradual decline in the use of fine-needle aspiration.[@b3-ott-8-2865] The aim of this study was to describe the trends and the present status of different diagnostic procedures in Shanghai and to analyze the various methods of obtaining core biopsies with respect to their diagnostic accuracy.

Methods
=======

Patient population
------------------

To estimate the changing diagnostic patterns of breast cancer in urban Shanghai, all breast cancers (invasive and in situ) and all needle biopsies (benign or malignant) diagnosed between January 2005 and December 2012 were selected from the Shanghai Cancer Data Base, which integrates information from almost 50% of patients with breast cancer in Shanghai. This is a retrospective study of 11,947 consecutive needle biopsies performed by experienced radiologists and surgeons specialized in needle biopsies.

The study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the institutional review board of Fudan University Shanghai Cancer Center. All the patients enrolled in this study signed the informed consent voluntarily.

Biopsy method
-------------

The surgeon and radiologist discussed the approach to each lesion, choosing the shortest route and skin entry site; they chose sites that could be comfortably included in future open surgery should cancer be diagnosed and avoided areas that could produce unsightly scars. After the radiographer had positioned the patient, the radiologist targeted the lesion and the surgeon performed the biopsy. The mode of percutaneous biopsy used was dependent upon the presenting lesion. The American College of Radiology guidelines for image-guided biopsy were followed. Ultrasound-guided core needle biopsy (UCNB) was preferentially used for all palpable and nonpalpable lesions that were visible by ultrasound. Approximately, five cores were taken from each lesion with a 14-gauge needle. Vacuum assistance was selectively used with UCNB based on tumor characteristics and was most often used for tumors that were less than 2 cm in size and considered benign. Stereotactic-guided biopsy was used for nonpalpable lesions not observed on ultrasonography, typically for microcalcifications or other imaging abnormalities observed by an initial mammography, but not identified by ultrasound. Vacuum assistance was used with stereotactic biopsies using a Suros (9-gauge) device, taking six to 12 cores per lesion. If the target lesion contained calcifications, a radiograph of the specimen was used to confirm the presence of calcifications in the cores. Analgesia for needle biopsies was accomplished with approximately 4--12 mL of buffered 1% lidocaine using a 26-gauge needle to anesthetize a cone of tissue around the lesion, as well as the needle track and associated skin. Skin punch biopsy was typically performed with a 4-mm instrument, and the wound was held together with DERMABOND^®^. The core tissue samples were immersed in 10% formalin solution and sent to the pathology laboratory for tissue processing.

Statistical analysis
--------------------

Simple descriptive statistics, such as mean ± standard deviation, median/range, and percentage were reported. The types of needle biopsies (core-needle or vacuum-assisted biopsy, X-ray or B-mode ultrasound-guided biopsy) and biopsy trends were analyzed. A secondary pathology review was performed for all needle biopsies, and patients whose cancer was diagnosed via needle biopsy were compared with patients whose cancer was diagnosed via surgical excision. When patients presented with more than one tumor, each cancer diagnosis was independently analyzed. Logistic regression was used to identify important predictors of biopsy type. By using multivariate logistic regression, we identified patient and tumor characteristics associated with the use of needle biopsy. We compared the histopathological findings of the needle biopsy specimens with those of surgical specimens or with each patient's long-term follow-up images. We also calculated the agreement, underestimation, sensitivity, and false-negative rates. The underestimation rate of CNB-diagnosed high-risk lesions was defined as the proportion of lesions diagnosed as high-risk by CNB that were upgraded to ductal carcinoma in situ (DCIS) or invasive cancer after surgical excision. The underestimation rate of CNB-diagnosed DCIS lesions was defined as the proportion of lesions diagnosed as DCIS by CNB, but upgraded to invasive cancer after surgical excision. Lesions which were not removed by subsequent surgical excision were excluded from the underestimation rate analysis. The false-negative rate was defined as the proportion of all breast cancers with a benign, high-risk, or inconclusive diagnosis on UCNB.

Results
=======

Constitution of preoperative diagnostic procedures in the Shanghai Cancer Center from 2005 to 2012
--------------------------------------------------------------------------------------------------

Over the 8-year period from 2005 to 2012, the Shanghai Cancer Center registered 11,947 UCNBs, 2,015 ultrasound-guided vacuum-assisted biopsies (UVABs), and 654 stereotactic X-ray guided vacuum-assisted biopsies (XVABs; [Tables 1](#t1-ott-8-2865){ref-type="table"} and [2](#t2-ott-8-2865){ref-type="table"}). A total of 81% of lesions diagnosed by CNB were determined to be malignant (n=9,673), whereas 5.5% were determined to be high-risk (n=655), and 13.5% were determined to be benign (n=1,619; [Table 1](#t1-ott-8-2865){ref-type="table"}). In these analyses, samples were determined to be high-risk when there was inadequate sample or a lesion of uncertain malignant potential as well as when malignancy was suspected. Image-guided needle biopsy was the initial procedure for approximately 80% (9,673 of 11,947) women who were considered to have malignant lesions. A diagnosis of cancer was made using microinvasive techniques for 106 of 167 (63.5%) cancers in the year 2005 and for 2,589 of 3,112 (83.2%) cancers in the year 2012, with an obvious rising trend.

However, only 49 (2.4%) and 129 (19.7%) of lesions were diagnosed as malignant or atypical on UVAB and stereotactic XVAB, respectively. The detailed pathological diagnoses for the malignant lesions and atypical ductal hyperplasia (ADH) identified by UVAB and stereotactic XVAB are presented in [Table 2](#t2-ott-8-2865){ref-type="table"}. When compared with year 2005, the number of UCNB, UVAB, and XVAB performed in 2012 increased by 18-fold, 12-fold, and twofold, respectively. The lesions diagnosed by UVAB were predominantly benign, (1,966 of 2,015 \[97.6%\] cases), whereas 35 cases diagnosed by UVAB were malignant; 80.3% of lesions diagnosed by XVAB were benign.

Trends in the patients choosing CNB versus OSB
----------------------------------------------

[Figure 1](#f1-ott-8-2865){ref-type="fig"} shows the percentage of patients undergoing CNB or OSB. The diagnostic patterns greatly changed during the past 8 years, with increasing numbers of patients choosing preoperative needle biopsy instead of intraoperative frozen section analysis. For patients who were diagnosed and ultimately underwent surgery in our hospital, the number of preoperative needle biopsies greatly increased. The ratio of lesions diagnosed by preoperative biopsy to those diagnosed by intraoperative frozen section analysis tremendously increased from 0.14 (103/731) to 4.6 (2,148/468).

[Figure 2](#f2-ott-8-2865){ref-type="fig"} shows the composition of diagnostic patterns of the patients who chose OSB in 2005 and 2012. Significant changes occurred in the lesion pattern from 2005 to 2012. In the year 2012, patients whose lesions were considered malignant were more likely to choose needle biopsy (388 of 731, or 53.16%) than surgical biopsy as their diagnostic procedure. Only patients who were not eligible for UCNB chose surgical biopsy as their diagnostic approach in 2012. Patients whose lesions were considered benign were also likely to choose surgical biopsy because benign lesions can be thoroughly treated using surgical biopsy.

Logistic regression model estimating the likelihood of initial needle biopsy
----------------------------------------------------------------------------

[Table 3](#t3-ott-8-2865){ref-type="table"} shows the results of a multivariate logistic regression model estimating the likelihood of initial needle biopsy. Women who came from the provinces near Shanghai were more likely to receive a needle biopsy than women living in Shanghai (odds ratio, 1.12; 95% confidence interval \[CI\], 1.01--1.25), after controlling for other variables. Women with tumors of lower stage, smaller size, or lower grade were less likely to receive initial needle biopsy. After controlling for patient and tumor characteristics, the choice of needle biopsy was associated with year of diagnosis, which remained a significant predictor of initial needle biopsy on logistic regression analysis.

Agreement between initial preoperative (needle biopsy) diagnosis and final pathological diagnosis
-------------------------------------------------------------------------------------------------

Based on our results, we calculated the accuracy, underestimation rate, and false-negative rate of CNB ([Table 4](#t4-ott-8-2865){ref-type="table"}). The total accuracy rate for the past 8 years was 92.4%, ranging from 89.8% in 2005 to 93.0% in 2012 with a gradual rising trend. The total underestimation rate of CNB-diagnosed lesions was 5.9% (709 of 11,947). These underestimation rates were calculated only for lesions that were subsequently excised surgically. The overall false-negative rate was 1.7%, with specific false-negative rates for UCNB, UVAB, and XVAB of 1.7%, 0%, and 0%, respectively. The kappa measure of agreement between the UCNB results and surgical excision findings or follow-up results was 0.924 (*P*\<0.001). In the year 2012, for example, in 3,112 patients who were diagnosed by UCNB, the false-negative rate was 1.2% (36 of 3,112), and the sensitivity was 98.2% (3,076 of 3,112).

We defined an ADH underestimate as the percutaneous diagnosis of ADH in a lesion shown to have DCIS/DCIS microinvasion (DCIS-mi)/invasive ductal carcinoma on surgical histology, a DCIS underestimate as the percutaneous diagnosis of DCIS in a lesion shown to have invasive cancer on surgical histology, and a phyllodes tumor (PLT) underestimate as the percutaneous diagnosis of papillary lesion (PL) in a lesion shown to have DCIS/invasive ductal carcinoma/intracystic papillary carcinomas on surgical histology. The overall accuracy rate of diagnostic CNB was 92.4%, and 709 patients (5.9%) had lesions that were underestimated, including 162 (22.8%) ADH, 435 (61.4%) DCIS, 91 (12.7%) PL, and 21 (2.9%) PLTs ([Table 5](#t5-ott-8-2865){ref-type="table"}).

Discussion
==========

CNB is a reliable procedure for detecting breast cancer without invasive surgery. Open biopsy procedures are not required in patients with histologically benign percutaneous biopsy results, if the imaging and pathological findings are concordant. However, patients with ADH, atypical lobular hyperplasia, or lobular carcinoma in situ found on percutaneous biopsy may have DCIS or invasive cancer at the same site and should generally undergo surgical excision.

The diagnostic accuracy of CNB is reported to be higher for nonpalpable lesions,[@b4-ott-8-2865],[@b5-ott-8-2865] and this procedure draws more attention from surgeons because they are impressed by the accuracy of CNB. CNB has been available in the People's Republic of China for breast biopsies since the 1990s. For palpable masses, CNB is the first-line test, whereas image-guided CNB is used for the diagnosis of image-detected breast abnormalities. Freehand or UCNB is less invasive, more cost-effective, and less time-consuming than surgical biopsy and yields comparable results.[@b6-ott-8-2865] There are relatively few patients for whom excisional biopsy should be the initial diagnostic procedure. For patients with a diagnosis of breast cancer, the goal is to make the diagnosis with a needle and to go to the operating room for treatment only once. A definitive diagnosis of breast cancer made using a minimally invasive needle biopsy permits optimal preoperative workup, patient counseling, and surgical planning.

Women commonly present in clinics for the evaluation of palpable breast masses in urban People's Republic of China. Compared with Western people, Chinese people lack awareness of breast self-examinations and health surveys, mostly because these issues receive less investment and less attention from the government. In the last decade, awareness of breast cancer has increased and diagnostic patterns have greatly changed in the People's Republic of China. CNB of the breast was introduced and combined with stereotactic (mammographic) or ultrasound guidance, the results were encouraging.[@b7-ott-8-2865] Over the last 8 years, we have performed a large number of core biopsies on breast lesions under ultrasound guidance. Of these, 81.0% of the samples were histopathologically determined to be malignant lesions, 5.5% were determined to be high-risk lesions, and 13.5% were determined to be benign lesions. In the year 2012, 2,589 of 3,112 (83.2%) cancers were determined to be malignant; this represents an obvious rising trend since 2005. Image-guided CNB is very accurate and was an acceptable diagnostic procedure prior to OSB.[@b8-ott-8-2865]--[@b12-ott-8-2865]

The results of the present study confirmed that UCNB is an accurate and reliable method for the diagnosis of breast lesions. The sensitivity of CNB was reported to range from 94% to 99%, and its specificity was reported to range from 99% to 100%.[@b13-ott-8-2865] In our study, we reviewed 11,947 cases of CNB of which most were performed using 14-gauge needles, and approximately four cores were taken per lesion. Our data identified the presence of breast lesions in women undergoing CNB for the past 8 years with an overall accuracy of approximately 92.4%, ranging from 89.8% in 2005 to 93.0% in 2012 with a gradual rising trend. The total underestimation rate of CNB-diagnosed lesions was 5.9% (709 of 11,947). It has been reported that needles larger than 16-gauge provide the most accurate diagnosis (in both sensitivity and specificity).[@b14-ott-8-2865] These reports also stress the importance of the number of cores taken during each biopsy; the accuracy and sensitivity for detecting nonpalpable breast lesions increase when six or more tissue samples are taken.[@b15-ott-8-2865],[@b16-ott-8-2865]

Over the past 10 years, minimally invasive breast biopsy systems have greatly developed.[@b17-ott-8-2865]--[@b22-ott-8-2865] As a minimally invasive detection method, the vacuum-assisted system provides a new choice for the excision of benign breast lesions and has been successfully applied in the excision of benign breast lesions in previous studies. This method is commonly used in the People's Republic of China to completely remove lesions that are considered benign, because this procedure is too expensive and not covered by insurance.

A special phenomenon can be found in our data: women who came from the provinces surrounding Shanghai were more likely to receive a needle biopsy than women living in Shanghai, after controlling for other variables. In general, Chinese people approach medicine very conservatively; they preferred traditional diagnostic methods such as OSB and needle biopsy because of the risk of triggering distant metastasis and leaving residual lesions. Patients who traveled to Shanghai from other provinces for further treatment were willing to choose newer and more effective medical treatments; patients have a very strong sense of trust for doctors. The lack of medical coverage for CNB may be another reason for the increased rate of CNB among patients living outside Shanghai.

There are certain limitations of our study. For instance, as a hospital-based study, we described the trends and the present status of different diagnostic procedures in Shanghai and determined the core biopsy diagnostic accuracy. Well-reported retrospective chart reviews, retrospective data-base analyses, or prospective diagnostic accuracy studies are needed to address unanswered questions about which factors affect the accuracy and reliability of breast CNB. In the future, it is anticipated that the results of cost-effectiveness studies will provide opportunities to optimize the criteria for selection of appropriate procedures on an individual basis, considering costs, and should influence the decision about the choice of the optimal sampling procedure.[@b23-ott-8-2865] In addition, further molecular biology analysis will be helpful to identify high-risk breast cancer patients who may benefit from the currently available breast biopsy methods.

Conclusion
==========

The use of preoperative needle biopsies for initial breast cancer diagnosis is acceptable in urban Shanghai and is now a standard procedure at the Shang Cancer Center. We mostly use UCNB to diagnose malignant tumors. UCNB is more common among those with larger tumors, and its prevalence has significantly increased over time. UCNB is an accurate diagnostic alternative to surgical biopsy in patients with breast lesions detected via ultrasound, although the high underestimation rates for DCIS and high-risk lesions are still a concern. Providers should consider needle biopsy when clinically feasible as the initial breast diagnostic procedure, because it may reduce the number of surgeries needed to treat breast cancer.

**Disclosure**

The authors report no conflicts of interest in this work.

![Trends in CNB and OSB procedures.\
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###### 

Ultrasound-guided core needle biopsies in the Shanghai Cancer Center

  Biopsies        2005      2006      2007      2008      2009      2010      2011      2012      Total
  --------------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  Total, N        167       606       1,001     1,245     1,510     1,931     2,375     3,112     11,947
  Total (%)       \(100\)   \(100\)   \(100\)   \(100\)   \(100\)   \(100\)   \(100\)   \(100\)   \(100\)
  Malignant, n    106       516       865       959       1,205     1,510     1,923     2,589     9,673
  Malignant (%)   (63.5)    (85.1)    (86.4)    (77.0)    (79.8)    (78.2)    (81.0)    (83.2)    (81.0)
  High-risk, n    17        31        42        103       90        93        99        180       655
  High-risk (%)   (10.2)    (5.1)     (4.2)     (8.3)     (6.0)     (4.8)     (4.2)     (5.8)     (5.5)
  Benign, n       44        59        94        183       215       328       353       343       1619
  Benign (%)      (26.3)    (9.7)     (9.4)     (14.7)    (14.2)    (17.0)    (14.8)    \(11\)    (13.5)

**Notes:** High-risk refers here to inadequate samples, lesions of uncertain malignant potential, and lesions where malignancy is suspected.

###### 

The pathologic results of UVAB and XVAB over the past 8 years

  Year    Ultrasound   X-ray                    
  ------- ------------ ------- ---- ----- ----- ----
  2004    68           1       0    50    7     6
  2005    83           1       1    38    7     5
  2006    127          0       0    88    22    1
  2007    152          1       0    83    14    3
  2008    161          0       4    115   18    3
  2009    279          4       0    79    5     0
  2010    440          3       2    110   16    7
  2011    705          25      7    91    13    2
  2012    1,027        28      11   87    10    3
  Total   2,015        35      14   654   102   27

**Abbreviations:** ADH, atypical ductal hyperplasia; UVAB, ultrasound-guided vacuum-assisted biopsy; XVAB, X-ray guided vacuum-assisted biopsy.

###### 

Patient, tumor, and system characteristics associated with needle biopsy as the initial diagnostic technique: the results of a multivariate logistic regression model

  Patient characteristics      Odds ratio   95% CI   
  ---------------------------- ------------ -------- ------
  **Age at diagnosis**         0.93         0.87     1.02
  **Tumor characteristics**                          
  Stage                                              
   Stage 0                     0.76         0.6      0.93
   Stage 1                     0.81         0.73     0.91
   Stage 2                     1.00         --       --
  Tumor size                                         
   \<2 cm                      0.92         0.86     0.98
   2--5 cm                     0.90         0.76     1.06
   Missing tumor size          0.92         0.82     1.04
   \>5 cm                      1.00         --       --
  Grade                                              
   Grade 1                     0.84         0.79     0.91
   Grade 2                     0.92         0.86     0.97
   Grade 3                     1.00         --       --
  **System characteristics**                         
  Birth city                                         
   Near province               1.12         1.01     1.25
   Other                       0.92         0.82     1.04
   Shanghai                    1.00         --       --
  Year of diagnosis                                  
   2005--2006                  0.74         0.68     0.80
   2007--2009                  0.89         0.85     0.94
   2010--2012                  1.00         --       --

**Abbreviation:** CI, confidence interval.

###### 

The accuracy rate, underestimation rate, and false-negative rate of CNB

  Year    Accuracy rate (%)   Underestimation rate (%)   False-negative rate (%)   Total (%)
  ------- ------------------- -------------------------- ------------------------- --------------
  2005    150 (89.8)          13 (7.8)                   4 (2.4)                   167 (100)
  2006    562 (92.7)          32 (5.3)                   12 (2.0)                  606 (100)
  2007    917 (91.6)          56 (5.6)                   28 (2.8)                  1,001 (100)
  2008    1,154 (92.7)        68 (5.5)                   23 (1.8)                  1,245 (100)
  2009    1,380 (91.4)        95 (6.3)                   35 (2.3)                  1,510 (100)
  2010    1,773 (91.8)        124 (6.4)                  34 (1.8)                  1,931 (100)
  2011    2,204 (92.8)        140 (5.9)                  31 (1.3)                  2,375 (100)
  2012    2,895 (93.0)        181 (5.8)                  36 (1.2)                  3,112 (100)
  Total   11,035 (92.4)       709 (5.9)                  203 (1.7)                 11,947 (100)

**Notes:** The accurate rate was defined as the proportion of lesions correctly identified as benign, malignant, or high-risk by CNB; underestimation rate refers to lesions of uncertain malignant potential (upstaged to DCIS or invasive cancer), lesions of uncertain malignant potential excluding ADH or atypical lobular hyperplasia (upstaged to DCIS or invasive cancer), ADH (upstaged to DCIS or invasive cancer), and DCIS (upstaged to invasive cancer) that were underestimated.

**Abbreviations:** CNB, core needle biopsy; DCIS, ductal carcinoma in situ; ADH, atypical ductal hyperplasia.

###### 

Analysis of CNB underestimation

  CNB diagnosis   Total cases[\*](#tfn6-ott-8-2865){ref-type="table-fn"}   Final diagnosis   Cases[\*\*](#tfn7-ott-8-2865){ref-type="table-fn"}   Percentage of total cases
  --------------- -------------------------------------------------------- ----------------- ---------------------------------------------------- ---------------------------
  ADH             162                                                      DCIS              51                                                   32.6
                                                                           DCIS-mi           56                                                   35.8
                                                                           IDC \<1 cm        25                                                   14.7
                                                                           IDC               30                                                   16.9
  DCIS            435                                                      DCIS-mi           202                                                  49.2
                                                                           Mainly DCIS       142                                                  31.5
                                                                           IDC               91                                                   19.3
  PL              91                                                       DCIS              25                                                   25.1
                                                                           IDC               25                                                   26.9
                                                                           IPC               40                                                   48
  Other           21                                                       PLT, etc          21                                                   100
  Total           709                                                                        709                                                  100

**Notes:**

Total number of cases according to CNB diagnosis.

Number of cases according to final diagnosis.

**Abbreviations:** CNB, core needle biopsy; ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; DCIS-mi, DCIS microinvasion; IDC, invasive ductal carcinoma; IPC, intracystic papillary carcinomas; PLT, phyllodes tumor; PL, papillary lesion.
